John S Bomalaski
Overview
Explore the profile of John S Bomalaski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdelrahman A, Sandow P, Wang J, Xu Z, Rojas M, Bomalaski J, et al.
Mol Metab
. 2024 Aug;
89:102020.
PMID: 39214514
Objective: Chronic inflammation and oxidative stress mediate the pathological progression of diabetic complications, like diabetic retinopathy (DR), peripheral neuropathy (DPN) and impaired wound healing. Studies have shown that treatment with...
2.
Rogers L, Kremer J, Brashears C, Lin Z, Hu Z, Bastos A, et al.
Clin Cancer Res
. 2023 Jun;
29(16):3189-3202.
PMID: 37339179
Purpose: Many cancers lack argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme of arginine biosynthesis. This deficiency causes arginine auxotrophy, targetable by extracellular arginine-degrading enzymes such as ADI-PEG20. Long-term tumor resistance...
3.
Kraehenbuehl L, Holland A, Armstrong E, OShea S, Mangarin L, Chekalil S, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681616
Metastatic uveal melanoma (UM) remains challenging to treat, with objective response rates to immune checkpoint blockade (ICB) being much lower than in primary cutaneous melanoma (CM). Besides a lower mutational...
4.
Chan P, Phillips M, Ellis S, Johnston A, Feng X, Arora A, et al.
Pigment Cell Melanoma Res
. 2022 Apr;
35(4):461-470.
PMID: 35466524
Metastatic uveal melanoma (UM) is a devastating disease with few treatment options. We evaluated the safety, tolerability and preliminary activity of arginine depletion using pegylated arginine deiminase (ADI-PEG20; pegargiminase) combined...
5.
Zhang Y, Higgins C, Van Tine B, Bomalaski J, DeBosch B
Cell Rep Med
. 2022 Feb;
3(1):100498.
PMID: 35106510
Obesity is a multi-systemic disorder of energy balance. Despite intense investigation, the determinants of energy homeostasis remain incompletely understood, and efficacious treatments against obesity and its complications are lacking. Here,...
6.
Harding J, Yang T, Chen Y, Feng Y, Yen C, Ho C, et al.
Cancer
. 2021 Aug;
127(24):4585-4593.
PMID: 34415578
Background: Arginine starvation depletes the micronutrients required for DNA synthesis and interferes with both thymidylate synthetase activity and DNA repair pathways in preclinical models of hepatocellular carcinoma (HCC). Pegylated arginine...
7.
Chang K, Chiang N, Wu S, Yen C, Chen S, Yeh Y, et al.
Oncoimmunology
. 2021 Jul;
10(1):1943253.
PMID: 34290906
Background: Pegylated arginine deiminase (ADI-PEG 20) is a metabolism-based strategy that depletes arginine, resulting in tumoral stress and cytotoxicity. Preclinically, ADI-PEG 20 modulates T-cell activity and enhances the therapeutic efficacy...
8.
Tsai H, Hsiao H, Hsu Y, Liu Y, Kao H, Liu T, et al.
Cancer Med
. 2021 Mar;
10(9):2946-2955.
PMID: 33787078
Most acute myeloid leukemia (AML) cells are argininosuccinate synthetase-deficient. Pegylated arginine deiminase (ADI-PEG20) monotherapy depletes circulating arginine, thereby selectively inducing tumor cell death. ADI-PEG20 was shown to induce complete responses...
9.
Hall P, Ready N, Johnston A, Bomalaski J, Venhaus R, Sheaff M, et al.
Clin Lung Cancer
. 2020 Aug;
21(6):527-533.
PMID: 32859536
Background: Pre-clinical studies indicated that arginine-deprivation therapy using pegylated arginine deiminase (pegargiminase, ADI-PEG 20) may be effective in patients with argininosuccinate synthetase 1 (ASS1)-deficient small-cell lung cancer (SCLC). Patients And...
10.
Singh P, Deorukhkar A, Venkatesulu B, Li X, Tailor R, Bomalaski J, et al.
Mol Cancer Ther
. 2019 Aug;
18(12):2381-2393.
PMID: 31395686
Distinct metabolic vulnerabilities of cancer cells compared with normal cells can potentially be exploited for therapeutic targeting. Deficiency of argininosuccinate synthetase-1 (ASS1) in pancreatic cancers creates auxotrophy for the semiessential...